Stock AnalizGSK plc GSK
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
GSK plc (GSK) is a healthcare company listed in the US with a market value of about $102.0B. In the twelve months to September 30, 2026 it had revenue of $44.3B and net income of $5.7B, a net margin of 13.0%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is value (4/5); the weakest is future growth (2/5).
Key numbers: a P/E of 17.9, a price to free cash flow of 12.3, 5-year revenue growth of 6% a year, a 5-year average ROIC of 16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 31% above the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Checks not passed
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.3B | $44.0B | $39.3B | $38.6B | $35.3B | $33.3B | $33.2B | $44.6B | $39.5B | $40.8B | $34.3B |
| Net income | $5.7B | $7.7B | $3.2B | $6.3B | $18.0B | $5.9B | $7.8B | $6.1B | $4.6B | $2.1B | $1.1B |
| Free cash flow | $8.3B | $8.6B | $6.5B | $6.9B | $7.5B | $9.4B | $10.2B | $8.9B | $9.1B | $7.3B | $6.1B |
| EPS (diluted) | $2.82 | $3.81 | $1.59 | $3.10 | $8.89 | $2.92 | $3.88 | $3.03 | $2.29 | $1.02 | $0.56 |
| Net margin | 13.0% | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% | 13.8% | 11.8% | 5.1% | 3.3% |
| ROIC | — | 19.8% | 11.1% | 18.8% | 17.8% | 10.8% | 14.1% | 14.1% | 15.5% | 14.8% | 7.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is GSK’s P/E ratio?
About 17.9, based on the last twelve months of diluted earnings per share (forward P/E about 10.2).
Is GSK stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 31% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does GSK pay a dividend?
Yes. The dividend yield is about 3.64%, and it has paid dividends for 9 years in our data.
Is GSK a good stock to buy?
We do not give buy or sell advice. GSK scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.